- Home
- FULC vs EPIX Comparison
FULC vs EPIX Comparison
Compare FULC & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- EPIX
- Stock Information
- Founded
- FULC 2015
- EPIX 2009
- Country
- FULC United States
- EPIX Canada
- Employees
- FULC N/A
- EPIX N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- EPIX Health Care
- Exchange
- FULC Nasdaq
- EPIX Nasdaq
- Market Cap
- FULC 221.5M
- EPIX 209.4M
- IPO Year
- FULC 2019
- EPIX N/A
- Fundamental
- Price
- FULC $3.25
- EPIX $1.83
- Analyst Decision
- FULC Hold
- EPIX Hold
- Analyst Count
- FULC 10
- EPIX 4
- Target Price
- FULC $7.44
- EPIX $9.50
- AVG Volume (30 Days)
- FULC 843.4K
- EPIX 2.4M
- Earning Date
- FULC 11-13-2024
- EPIX 12-10-2024
- Dividend Yield
- FULC N/A
- EPIX N/A
- EPS Growth
- FULC N/A
- EPIX N/A
- EPS
- FULC N/A
- EPIX N/A
- Revenue
- FULC $80,871,000.00
- EPIX N/A
- Revenue This Year
- FULC $2,821.96
- EPIX N/A
- Revenue Next Year
- FULC N/A
- EPIX N/A
- P/E Ratio
- FULC N/A
- EPIX N/A
- Revenue Growth
- FULC 2987.86
- EPIX N/A
- 52 Week Low
- FULC $2.86
- EPIX $1.40
- 52 Week High
- FULC $13.70
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- FULC 44.64
- EPIX 26.56
- Support Level
- FULC $2.86
- EPIX $1.66
- Resistance Level
- FULC $3.94
- EPIX $1.89
- Average True Range (ATR)
- FULC 0.23
- EPIX 0.12
- MACD
- FULC 0.02
- EPIX 0.08
- Stochastic Oscillator
- FULC 36.11
- EPIX 79.31
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.